Loading...
XSHE
000739
Market cap2.32bUSD
Jun 03, Last price  
14.39CNY
1D
2.79%
1Q
-17.06%
Jan 2017
91.10%
Name

Apeloa Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
16.17
P/S
1.39
EPS
0.89
Div Yield, %
2.20%
Shrs. gr., 5y
-0.26%
Rev. gr., 5y
10.76%
Revenues
12.02b
+4.77%
1,035,415,6291,148,555,7221,041,520,3171,250,445,8701,367,853,6941,520,985,2521,534,475,7273,480,088,2173,899,764,8344,232,760,1434,337,941,1874,772,188,8785,551,763,0656,376,400,6387,210,711,3867,879,672,7438,942,618,23210,544,905,37711,474,162,36512,021,863,029
Net income
1.03b
-2.29%
43,754,89851,956,80530,442,82229,058,94434,085,09423,789,2798,249,414137,133,177167,358,826322,164,386208,230,302262,897,084256,592,089370,566,842553,400,761816,730,067955,550,170989,173,6751,055,340,7401,031,121,698
CFO
1.21b
+17.20%
87,395,223159,428,595174,198,82794,568,648208,298,453121,045,562181,737,964335,901,418190,445,544786,637,638441,161,691180,419,814209,799,349832,692,2741,360,066,1901,059,526,132611,748,7281,326,107,3161,031,363,0741,208,753,683
Dividend
May 23, 20240.31691 CNY/sh

Profile

Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China.
URL
http://www.apeloa.com
IPO date
May 09, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
12,021,863
4.77%
11,474,162
8.81%
10,544,905
17.92%
Cost of revenue
10,379,656
9,833,407
9,167,113
Unusual Expense (Income)
NOPBT
1,642,207
1,640,756
1,377,792
NOPBT Margin
13.66%
14.30%
13.07%
Operating Taxes
172,444
149,337
22,894
Tax Rate
10.50%
9.10%
1.66%
NOPAT
1,469,764
1,491,418
1,354,898
Net income
1,031,122
-2.29%
1,055,341
6.69%
989,174
3.52%
Dividends
(335,879)
Dividend yield
1.33%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
814,026
807,796
571,865
Long-term debt
97,606
27,660
281,249
Deferred revenue
31,686
30,620
15,120
Other long-term liabilities
36,000
72,000
72,000
Net debt
(2,749,987)
(2,919,278)
(2,791,152)
Cash flow
Cash from operating activities
1,208,754
1,031,363
1,326,107
CAPEX
(630,467)
Cash from investing activities
(676,423)
Cash from financing activities
(301,859)
FCF
1,312,219
1,279,915
631,957
Balance
Cash
3,661,619
3,580,687
3,552,948
Long term investments
2
174,047
91,318
Excess cash
3,060,526
3,181,026
3,117,021
Stockholders' equity
6,310,546
5,994,545
5,283,354
Invested Capital
4,654,899
3,982,995
3,209,065
ROIC
34.03%
41.47%
41.69%
ROCE
21.05%
22.58%
21.38%
EV
Common stock shares outstanding
1,163,269
1,169,353
1,169,324
Price
16.26
5.65%
15.39
-28.55%
21.54
-38.61%
Market cap
18,914,755
5.10%
17,996,337
-28.55%
25,187,231
-39.09%
EV
16,172,687
15,084,747
22,403,426
EBITDA
2,220,225
2,193,813
1,767,224
EV/EBITDA
7.28
6.88
12.68
Interest
28,582
34,230
59,230
Interest/NOPBT
1.74%
2.09%
4.30%